BACKGROUND: Dose-finding phase I trials in children are usually carried out once clinical data have already been accumulated in the adult population. The objectives, place and role of paediatric dose-finding trials are investigated in the era of molecularly targeted agents (MTAs). METHODS: Phase I paediatric oncology trials of MTAs approved in adults before June 15th, 2012 were reviewed. The recommended phase II dose (RPIID) was compared to the body surface area (BSA)-adjusted approved dose in adults. Toxicity profile was compared to the findings from the corresponding adult phase I trials. RESULTS: Fifteen MTAs out of a total of 25 MTAs approved in the adult population have been evaluated in 19 single-agent phase I paediatric trials. Trials included a median of 30 children with a median of four dose levels. The paediatric RPIID ranged between 90% and 130% of the BSA-adjusted approved dose in adults for 70% of the trials (75% of compounds). Overall, 63% of children did not receive an optimal dose. The most marked discrepancy involved sunitinib. Safety profiles described in phase I paediatric trials were usually similar to those reported in the adult population. CONCLUSIONS: These data suggest that dose-finding studies might not be necessary for all the MTAs in children. Except in the case of a narrow therapeutic index, early-phase trials validating pharmacokinetics, pharmacodynamic markers and efficacy findings from adults while controlling for toxicity appear to be a possible alternative to accelerate drug development in paediatric oncology.
BACKGROUND: Dose-finding phase I trials in children are usually carried out once clinical data have already been accumulated in the adult population. The objectives, place and role of paediatric dose-finding trials are investigated in the era of molecularly targeted agents (MTAs). METHODS: Phase I paediatric oncology trials of MTAs approved in adults before June 15th, 2012 were reviewed. The recommended phase II dose (RPIID) was compared to the body surface area (BSA)-adjusted approved dose in adults. Toxicity profile was compared to the findings from the corresponding adult phase I trials. RESULTS: Fifteen MTAs out of a total of 25 MTAs approved in the adult population have been evaluated in 19 single-agent phase I paediatric trials. Trials included a median of 30 children with a median of four dose levels. The paediatric RPIID ranged between 90% and 130% of the BSA-adjusted approved dose in adults for 70% of the trials (75% of compounds). Overall, 63% of children did not receive an optimal dose. The most marked discrepancy involved sunitinib. Safety profiles described in phase I paediatric trials were usually similar to those reported in the adult population. CONCLUSIONS: These data suggest that dose-finding studies might not be necessary for all the MTAs in children. Except in the case of a narrow therapeutic index, early-phase trials validating pharmacokinetics, pharmacodynamic markers and efficacy findings from adults while controlling for toxicity appear to be a possible alternative to accelerate drug development in paediatric oncology.
Authors: Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal Journal: Nat Rev Clin Oncol Date: 2017-05-16 Impact factor: 66.675
Authors: Jaclynne H Nader; Dylan V Neel; David S Shulman; Clement Ma; Florence Bourgeois; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2020-09-04 Impact factor: 3.167
Authors: Eric J Chow; Zoltan Antal; Louis S Constine; Rebecca Gardner; W Hamish Wallace; Brent R Weil; Jennifer M Yeh; Elizabeth Fox Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Steven E Lipshultz; Melissa B Diamond; Vivian I Franco; Sanjeev Aggarwal; Kasey Leger; Maria Verônica Santos; Stephen E Sallan; Eric J Chow Journal: Paediatr Drugs Date: 2014-10 Impact factor: 3.022
Authors: Theodore W Laetsch; Steven G DuBois; Julia Glade Bender; Margaret E Macy; Lucas Moreno Journal: Cancer Discov Date: 2020-12-04 Impact factor: 38.272
Authors: N Gaspar; L V Marshall; D Binner; R Herold; R Rousseau; P Blanc; R Capdeville; J Carleer; C Copland; Y Kerloeguen; K Norga; L Pacaud; M-A Sevaux; C Spadoni; J Sterba; F Ligas; T Taube; M Uttenreuther-Fischer; S Chioato; M A O'Connell; B Geoerger; J-Y Blay; J C Soria; S Kaye; B Wulff; L Brugières; G Vassal; A D J Pearson Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976
Authors: April V P Clyburne-Sherin; Pravheen Thurairajah; Mufiza Z Kapadia; Margaret Sampson; Winnie W Y Chan; Martin Offringa Journal: Trials Date: 2015-09-18 Impact factor: 2.279